Research Studies
Back to Results
An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure
Description
The purpose of this study is to test the safety and effectiveness of the study drug, avatrombopag, in subjects with thrombocytopenia undergoing an operation. Patients will receive either 60mg or 80mg of avatrombopag once daily by mouth for 5 days prior to surgery
MoreDetails
Age
Adult
Eligibility
Adult, undergoing surgery to critical site (i.e. spine), low platelet count prior to surgery
Detailed Eligibility: Can not have: history of blood clots, be on anticoagulant or antiplatelet therapy prior to surgery, alcohol dependence, active infection, significant cardiovascular disease, current malignancy, hepatic encephalopathy or hepatocellular carcinoma.
Phase
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Type of Study
Treatment
Location
University of Colorado Hospital
Principal Investigator
Peter Witt, MD
Study ID
Protocol Number: 18-0546
More information available at ClinicalTrials.gov: NCT03326843
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers